Navigation Links
Scientists unravel resistance to breast cancer treatment
Date:10/31/2012

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

Tamoxifen used alongside traditional chemotherapy and radiotherapy blocks the female hormone oestrogen that, in certain breast cancers, is required by the tumour to grow; it has been shown to improve cancer survival rates by up to one third.

However, about one third of patients with the appropriate type of breast cancer known as oestrogen receptor positive breast cancer do not respond to tamoxifen or develop resistance to the drug. Oestrogen receptor positive breast cancer is the most common form of the disease accounting for 70% of cases.

Now, a team from the University of Manchester's Paterson Institute for Cancer Research has identified a molecular flag or biomarker that will help doctors predict which patients will respond best to complementary (adjuvant) hormone therapy with tamoxifen.

"The identification of molecular flags to classify subgroups of breast cancer and so determine the best treatment for each patient is of increasing importance in cancer therapy," said study lead Professor Gran Landberg.

"Tamoxifen has been shown to be highly effective in some breast cancer patients when used alongside traditional cancer therapies but, in a third of cases, the result has not been what we would hope. If we can predict which patients will respond to tamoxifen, and those who won't, then this is clearly advantageous as it means the correct treatment is provided instantly which will improve disease outcomes."

The research, funded by the charity Breakthrough Breast Cancer and published in the journal PLoS One, looked at the connective tissue surrounding the tumour, which is known to send signals that help the cancer to grow. The team, part of the Manchester Cancer Research Centre, found that fibroblast cells the cells that make up connective tissue in our bodies differ in their characteristics from patient to patient and can give clues about tamoxifen treatment response

Co-author Dr Susann Busch said: "We analysed tissue samples from 564 women with invasive breast cancer, some of whom were given tamoxifen and some who weren't; this allowed us to make a comparison between treatment responses.

"We discovered that women who had low levels of a protein known as pERK in their cancer-associated fibroblasts did not respond to tamoxifen. Testing patients for the pERK flag could help doctors determine whether tamoxifen is an appropriate treatment for their patient or whether alternative therapies should be explored, so saving time and money."

The researchers now plan to further study molecular flags that are characteristic for cancer-associated fibroblasts. Understanding how fibroblasts help the tumour to grow will allow the development of new strategies to block their harmful signals and overcome drug resistance.


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related biology news :

1. Stanford scientists build the first all-carbon solar cell
2. Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrigs disease
3. Scientists deepen genetic understanding of MS
4. Whitehead scientists identify major flaw in standard approach to global gene expression analysis
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Scientists uncover mechanism by which plants inherit epigenetic modifications
7. CT scan and 3-D print help scientists reconstruct an ancient mollusk
8. Scientists conclude high fructose corn syrup should not be blamed for obesity
9. Maintaining Earths sustainability: Scientists, engineers, educators take coordinated approach
10. UMN scientists get federal grant for biotechnology development to purify fracking water
11. Scientists reveal how natural antibiotic kills tuberculosis bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology: